TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27871699

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) with a bonded acrylic expander
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RME group
Number of subjects: 36
Study: 25122121

Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg tribendimidine
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 200 mg tribendimidine twice daily
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 75 mg/kg praziquantel divided in four doses within 2 days
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg mebendazole
Number of subjects: 156
Study: 21748413

Group type: EXPERIMENTAL
Intervention: Simple Vote ensemble classifier
Number of subjects: 77495

Group type: EXPERIMENTAL
Intervention: Weighted Vote ensemble classifier
Number of subjects: 77495

Group type: COMPARATOR
Intervention: Individual classifiers
Number of subjects: 77495
Study: 21098435

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 509

Group type: COMPARATOR
Intervention: RFCA
Number of subjects: 509
Study: 18674471

Group type: EXPERIMENTAL
Intervention: 80 mg/d atorvastatin
Number of subjects: 10001

Group type: COMPARATOR
Intervention: 10 mg/d atorvastatin
Number of subjects: 10001
Study: 16438370

Group type: EXPERIMENTAL
Intervention: Vaxigrip vaccine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Arbidol
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Combination of Vaxigrip and Arbidol
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study: 12721777

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10863494

Group type: EXPERIMENTAL
Intervention: Bright Smiles, Bright Future curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 8719072

Group type: EXPERIMENTAL
Intervention: Tongue exertion on fluid-filled bulb, exerting from 10 to 100% of maximal effort in 10% increments.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hand exertion on fluid-filled bulb, exerting from 10 to 100% of maximal effort in 10% increments.
Number of subjects: 20
Study: 2331082

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thiopentone and halothane
Number of subjects: 20
Study: 6446446

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxytetracycline
Number of subjects: 0
Study: 29917115

Group type: EXPERIMENTAL
Intervention: iPad-based cognitive rehabilitation program (3 hours per week for 10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group (no intervention during the study period)
Number of subjects: 0
Study: 27564431

Group type: EXPERIMENTAL
Intervention: RAPID3 remission (score ≤3)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: RAPID3 + 1 SJC (score ≤3 + 1 swollen joint)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: SDAI remission (score ≤3.3)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Boolean remission (all ≤1)
Number of subjects: 690
Study: 25947165

Group type: EXPERIMENTAL
Intervention: Vaccination with recombinant viral vectors chimpanzee adenovirus 63 (ChAd63) and modified vaccinia Ankara (MVA) encoding ME-TRAP.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: T cell responses to TRAP peptides 21 to 30.
Number of subjects: 121

Group type: COMPARATOR
Intervention: Rabies vaccine (control).
Number of subjects: 121
Study: 24078508

Group type: EXPERIMENTAL
Intervention: Doxazosin (2 mg at night for two weeks, increasing to 4 mg for a further two weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin (20 μg at night)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin
Number of subjects: 31
Study: 21491106

Group type: EXPERIMENTAL
Intervention: Oral Phe load (100 mg/kg body weight) administered to PKU patients prior to one fMRI session (placebo-controlled)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral Phe load (100 mg/kg body weight)
Number of subjects: 17
Study: 19430718

Group type: EXPERIMENTAL
Intervention: Biopsy of pancreas
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Biopsy of gastric mucosa
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Biopsy of liver
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Biopsy of bile duct
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Biopsy of duodenal papilla
Number of subjects: 39

Group type: COMPARATOR
Intervention: Biopsy of gastric mucosa in pancreatic cancer patients (control group)
Number of subjects: 39
Study: 16352812

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 586

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 586
Study: 15197438

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Invasive mechanical ventilation (Control)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: NIV (successful cases)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: NIV (failed cases)
Number of subjects: 128
Study: 11195719

Group type: EXPERIMENTAL
Intervention: 100 ms SOA with target from the same location as the cue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 700 ms SOA with target and cue from different locations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual task with eye movements required (Experiment 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual task without eye movements (Experiment 2)
Number of subjects: 0
Study: 9252775

Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1.5% beta-lipohydroxyacid
Number of subjects: 6

Group type: COMPARATOR
Intervention: 5% salicylic acid
Number of subjects: 6

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 6
Study: 7543781

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no G-CSF)
Number of subjects: 14
Study: 2655681

Group type: EXPERIMENTAL
Intervention: Frusemide 10 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Frusemide 100 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bumetanide 2.5 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bumetanide 250 micrograms
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 319892

Group type: EXPERIMENTAL
Intervention: Primary additive hormone therapy followed by adrenalectomy
Number of subjects: 226

Group type: COMPARATOR
Intervention: Primary adrenalectomy followed by chemotherapy and/or additive hormone therapy
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Oophorectomy followed by adrenalectomy
Number of subjects: 226

Group type: COMPARATOR
Intervention: Adrenalectomy-oophorectomy as primary mode of therapy
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Sequential hormonal manipulation
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Secondary adrenalectomy
Number of subjects: 226
Study: 30803143

Group type: EXPERIMENTAL
Intervention: DSEK
Number of subjects: 74

Group type: COMPARATOR
Intervention: DSAEK
Number of subjects: 74
Study: 28575496

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (r‐ESWT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (home exercises only)
Number of subjects: 54
Study: 25858976

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Cerebrovascular events (overall)
Number of subjects: 3602
Study: 24598503

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) with enamel matrix derivative (EMD) and acellular dermis matrix (ADM)
Number of subjects: 20
Study: 22930088

Group type: EXPERIMENTAL
Intervention: Lateral pharyngoplasty (group 1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Z‐palatoplasty (group 2)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined surgery (group 3)
Number of subjects: 35
Study: 19618229

Group type: EXPERIMENTAL
Intervention: Functional dysphagia therapy with PEG feeding (group 1, n=59)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Functional dysphagia therapy without PEG feeding (group 2, n=105)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Early placement of PEG
Number of subjects: 164

Group type: COMPARATOR
Intervention: Complications and mortality in group 1 (PEG feeding)
Number of subjects: 164
Study: 17697262

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) induced by 10‐min hiliar clamping before organ recovery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CTL)
Number of subjects: 60
Study: 15219637

Group type: EXPERIMENTAL
Intervention: G331A polymorphism in the progesterone receptor gene
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PROGINS polymorphism in the progesterone receptor gene
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (452 controls)
Number of subjects: 72
Study: 11588508

Group type: EXPERIMENTAL
Intervention: Didanosine enteric-coated capsules (Videx EC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Didanosine tablets
Number of subjects: 42
Study: 9332685

Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy with cisplatin (20 mg/m2/day) and fluorouracil (200 mg/m2/day) for five consecutive days (CF)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy with vinblastine and bleomycin followed by standard radiotherapy (VBM)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Sequential VBM and radiation
Number of subjects: 273

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 273
Study: 8242299

Group type: EXPERIMENTAL
Intervention: Suture length to wound length ratio >= 4
Number of subjects: 454

Group type: COMPARATOR
Intervention: Suture length to wound length ratio < 4
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Overall incidence of wound infection
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Wound dehiscence requiring reoperation
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Incisional hernia after 12 months
Number of subjects: 454
Study: 3465787

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1,000 mg before surgery
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg administered at fixed intervals after surgery
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1,000 mg before surgery with acetaminophen as needed after surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo before surgery
Number of subjects: 75
Study: 30868491

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 3 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Unchanged pharmacological anti-arrhythmia therapy
Number of subjects: 64
Study: 30428834

Group type: EXPERIMENTAL
Intervention: Fourth Research Paradigm
Number of subjects: 0
Study: 26873501

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) - 2 sessions weekly for 5 weeks, using a 980-nm AlGaAs diode laser at 300 mW, delivering a Fluence of 10 J/cm²
Number of subjects: 33

Group type: COMPARATOR
Intervention: Clonazepam - half a tablet (2 mg) in the mouth for 3 min, three times a day for 21 days
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Comparison of LLLT and Clonazepam
Number of subjects: 33
Study: 25218533

Group type: EXPERIMENTAL
Intervention: Acadesine (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 22752860

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 301

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 301
Study: 20012197

Group type: EXPERIMENTAL
Intervention: In SHAPE health promotion program
Number of subjects: 76
Study: 17620074

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with 200,000 SQ-U
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with 24,000 SQ-U
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16238883

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural anger treatment (AT group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine care waiting-list control (RC group)
Number of subjects: 40
Study: 12219663

Group type: EXPERIMENTAL
Intervention: Verum ESWT (3 x 2000 pulses, ED+ of 0.33 mJ/mm2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham ESWT
Number of subjects: 40
Study: 10553822

Group type: EXPERIMENTAL
Intervention: 6% low molecular weight hydroxyethyl starch (HES 70/0.5)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6% medium‐molecular weight hydroxyethyl starch (HES 200/0.5)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modified gelatin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 30
Study: 7605855

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg) without gastritis
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg) with normal gastric emptying
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo with normal gastric emptying
Number of subjects: 61
Study: 2342849

Group type: EXPERIMENTAL
Intervention: Long-term residence group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Short-term residence group
Number of subjects: 24
Study: 7324888

Group type: EXPERIMENTAL
Intervention: Paraffin‐based neutral eye ointment Ph. Nord. 63
Number of subjects: 47

Group type: COMPARATOR
Intervention: Water‐based Methyl cellulose (MC) 4%
Number of subjects: 47
Study: 30744542

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 401

Group type: COMPARATOR
Intervention: CT
Number of subjects: 401
Study: 28067945

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) for weight loss through reduced caloric intake and increased physical activity
Number of subjects: 3751

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 3751
Study: 26537198

Group type: EXPERIMENTAL
Intervention: High-EX (286 +/‐ 40 min per week)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Middle-EX (129 +/‐ 4 min per week)
Number of subjects: 98

Group type: COMPARATOR
Intervention: CON (health education control)
Number of subjects: 98
Study: 23379637

Group type: EXPERIMENTAL
Intervention: Accu-Chek 360° View tool
Number of subjects: 0
Study: 21835452

Group type: EXPERIMENTAL
Intervention: GnRH (0.004 mg buserelin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: hCG (500 IU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (inseminated 16-18 hours after onset of detected estrus)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GnRH and hCG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 19421185

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) once weekly for 3 weeks
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) once daily for 21 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) at weekly doses > or = 25 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) at daily doses > or = 2.5 mg
Number of subjects: 2
Study: 17216683

Group type: EXPERIMENTAL
Intervention: Combined exercise and sleeping neck support pillow
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Active neck exercises
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Sleeping neck support pillow
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo control (hot or cold packs and massage)
Number of subjects: 128
Study: 15145970

Group type: EXPERIMENTAL
Intervention: M100240 50 mg once daily
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: M100240 25 mg three times daily or 50 mg twice daily
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: M100240 up to 50 mg once daily
Number of subjects: 251
Study: 11586054

Group type: EXPERIMENTAL
Intervention: 100 mg trazodone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 9670381

Group type: COMPARATOR
Intervention: FES‐IC (Functional Electrical Stimulation - Isometric Contractions)
Number of subjects: 26

Group type: COMPARATOR
Intervention: FES‐CE (Functional Electrical Stimulation - Cycle Ergometry)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 7758394

Group type: EXPERIMENTAL
Intervention: Arbekacin (ABK) alone
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Arbekacin (ABK) in combination with other compounds
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Arbekacin (ABK) in pneumonia cases
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Arbekacin (ABK) in patients pretreated with other drugs
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Efficacy ratio at 30 min
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Efficacy ratio at 60 min
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Adverse effects of ABK
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Abnormal laboratory findings
Number of subjects: 348
Study: 2738208

Group type: EXPERIMENTAL
Intervention: Informational intervention entailing descriptions of the experience in concrete objective terms
Number of subjects: 84

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 84
Study: 31857204

Group type: EXPERIMENTAL
Intervention: LSD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiagabine (control)
Number of subjects: 0
Study: 31267695

Group type: EXPERIMENTAL
Intervention: Girls on the Move intervention
Number of subjects: 1519
Study: 28914446

Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Baseline WBC count
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Concomitant use of biologic drugs
Number of subjects: 695
Study: 25943574

Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy (FOLFOX or FOLFIRI) plus panitumumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple chemotherapy (FOLFOXIRI) plus bevacizumab
Number of subjects: 0
Study: 23177481

Group type: EXPERIMENTAL
Intervention: Strength training (S; n = 30)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Endurance training (E; n = 30)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training (SE; n = 30)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Diet and physical activity recommendations (D; n = 29)
Number of subjects: 119
Study: 21962064

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 18261575

Group type: EXPERIMENTAL
Intervention: Alendronate + Alfacalcidol (10 mg/d + 0.5 microg/d)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (0.5 microg/d)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (T scores > -1)
Number of subjects: 64
Study: 16645021

Group type: EXPERIMENTAL
Intervention: Lipid-heparin emulsion (LHE) infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 15
Study: 14639354

Group type: EXPERIMENTAL
Intervention: Duct-to-mucosa anastomosis (group A)
Number of subjects: 144

Group type: COMPARATOR
Intervention: 1-layer end-to-side pancreaticojejunostomy (group B)
Number of subjects: 144
Study: 11139967

Group type: EXPERIMENTAL
Intervention: Microvolt level T wave alternans (TWA) positive
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Microvolt level T wave alternans (TWA) negative
Number of subjects: 221

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 221
Study: 8854366

Group type: EXPERIMENTAL
Intervention: Active nicotine inhaler
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 1474476

Group type: EXPERIMENTAL
Intervention: Conventional floss
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flossing device with chlorhexidine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flossing device with placebo
Number of subjects: 52
Study: 6091392

Group type: EXPERIMENTAL
Intervention: Misonidazole (11 g/m2 over four weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 30540995

Group type: EXPERIMENTAL
Intervention: African American women (AA)
Number of subjects: 758

Group type: COMPARATOR
Intervention: Non-African American women (NAA)
Number of subjects: 758
Study: 29986765

Group type: EXPERIMENTAL
Intervention: Enhanced REP (facilitation strategies)
Number of subjects: 3075

Group type: COMPARATOR
Intervention: Standard REP
Number of subjects: 3075
Study: 26081039

Group type: EXPERIMENTAL
Intervention: Rinsing with 15 ml of water for 30 seconds
Number of subjects: 50

Group type: COMPARATOR
Intervention: Drinking 200 ml of water within 30 seconds
Number of subjects: 50
Study: 24801218

Group type: EXPERIMENTAL
Intervention: PF‐04447943 25 mg q12h
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 22537246

Group type: EXPERIMENTAL
Intervention: English word-object pairings (CVCV and CCVC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Japanese word-object pairings (CVCV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Czech word-object pairings (CCVC)
Number of subjects: 60